RedHill Biopharma announced that RHB-107 has been accepted for inclusion in the Austere environments Consortium for Enhanced Sepsis Outcomes’ U.S. Government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment to be conducted in the U.S., Thailand, Ivory Coast and South Africa. The Company also announced that the Phase 2 study, predominantly funded by the U.S. Government Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, has received FDA clearance to start and is estimated to be completed by end of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RDHL:
- RedHill Biopharma announces registered direct offering, warrant exercise
- RedHill Biopharma announces U.S. government funding for Opaganib development
- Biotech Alert: Searches spiking for these stocks today
- RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights
Questions or Comments about the article? Write to editor@tipranks.com